CONCANAMYCIN A

Bezeichnung:CONCANAMYCIN A

CAS-Nr80890-47-7

Englisch Name:CONCANAMYCIN A

CBNumberCB9696475

SummenformelC46H75NO14

Molgewicht866.09

MOL-Datei80890-47-7.mol

CONCANAMYCIN A physikalisch-chemischer Eigenschaften

Schmelzpunkt	179-180℃ (dichloromethane ethanol )
Siedepunkt	966.4±65.0 °C(Predicted)
Dichte	1.20±0.1 g/cm3(Predicted)
storage temp.	−20°C
Löslichkeit	Soluble in DMSO
Aggregatzustand	Lyophilized solid
pka	12.46±0.70(Predicted)
Farbe	White
BRN	3560277
Stabilität	Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.

Sicherheit

Kennzeichnung gefährlicher	T+
R-Sätze:	26/27/28-36
S-Sätze:	26-36/37/39-45
RIDADR	UN 3462 6.1/PG 2
WGK Germany	3
RTECS-Nr.	CB9732000
F	10-21
HazardClass	6.1(b)
PackingGroup	III
HS Code	2941900000

Gefahreninformationscode (GHS)

CONCANAMYCIN A Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R26/27/28:Sehr giftig beim Einatmen, Verschlucken und Berührung mit der Haut.
R36:Reizt die Augen.
S-Sätze Betriebsanweisung:
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).
Beschreibung
Concanamycin A (80890-47-7) is a potent and specific inhibitor of the vacuolar (V-type) H+-ATPase which can induce apoptotic cell death in various cell lines.1,2?Inhibits cell surface expression of virus envelope glycoproteins.3?Dramatically increases the rate of extracellular vesicle release from a variety of cell types.4?Inhibits autophagy by blocking lysosomal acidification.5
Verwenden
Concanamycin A has been used:
- as a lysosomal inhibitor in young and old fibroblasts
- as a vacuolar-type H⁺-ATPase inhibitor in presynaptic vesicles
- as a lysosomal acidification blocker in HepG2 hepatocytes cells
Verwenden
Concanamycin A is the major analogue of the concanamycin complex produced by Streptomyces sp.. It has been shown to act as a potent and specific vacuolar-ATPase inhibitor. Concanamycin A inhibits the acidification of organelles and blocks cell surface expression of viral envelope glycoproteins without affecting their synthesis. It also interferes with intracellular protein trafficking and inhibits perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. Concanamycins are structurally related to the bafilomycins.
Definition
ChEBI: A concanamycin in which the lactone ring contains 4 double bonds and is substituted by 4 methyl groups, 2 hydroxy groups, 2 methoxy groups and an ethyl group.
Allgemeine Beschreibung
Chemical structure: macrolide
Biologische Aktivität
Specific inhibitor of V-type (vacuolar) H + -ATPase that displays > 2000-fold selectivity over other H + -ATPases (IC 50 values are 9.2, > 20000, > 20000 and > 20000 nM for yeast V-type, F-type, P-type H + -ATPases and porcine P-type Na + ,K + -ATPase respectively). Blocks cell surface expression of virus envelope glycoproteins without affecting synthesis and exhibits cytotoxicity in several cell lines.
Biochem/physiol Actions
Concanamycin A (ConA) inhibits acidification of organelles and perforin-mediated cytotoxicity. It is a vacuolar-type v-ATPase inhibitor. ConA possesses antiprotozoal and antineoplastic properties. It mediates inhibition of the negative factor (Nef) protein of the human immunodeficiency virus.
Lager
Store at -20°C
Einzelnachweise
1) Nishihara?et al.?(1995),?Specific inhibitors if vacuolar type H(+)-ATPases induce apoptotic cell death; Biochem. Biophys, Res. Commun.,?212?255 2) Hong?et al. (2006),?Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells; J. Pharmacol. Exp. Ther.,?319?672 3) Muroi?et al.?(1993),?Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus; Cell Struct. Function,?18?139 4) Cashikar and Hanson (1987),?A cell-based assay for CD63-containing extracellular vesicles; PLoS One,?14?e0220007 5) Gradzka?et al.?(2018),?Inhibitor of apoptosis proteins are required for effective fusion of autophagosomes with lysosomes; Cell Death Dis.,?9?529

CONCANAMYCIN A Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

80890-47-7, CONCANAMYCIN A Verwandte Suche:

Send Inquriy